Clinical trial
Voriconazole Versus Itraconazole In Primary Prophylaxis Of Invasive Fungal…
NCT00289991 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00289991 |
|---|---|
| Title | Voriconazole Versus Itraconazole In Primary Prophylaxis Of Invasive Fungal Infection (IFI) In Subjects With Allogeneic Hematopoietic Stem Cell Transplants (HSCT) |
| Official title | Prospective, Open-Label, Comparative, Multi-Center Study Of Voriconazole Compared To Itraconazole For The Primary Prophylaxis Of Invasive Fungal Infection (IFI) With Allogeneic Hematopoietic Stem Cell Transplants (HSCT) |
| Acronym | IMPROVIT |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Antifungal Prophylaxis of Invasive Fungal Infections |
| Intervention type | Drug |
| Interventions | Itraconazole, Vfend - voriconazole |
| Enrollment | 489 |
| Start date | Mar 1, 2006 |
| Primary completion | Feb 1, 2009 |
| Completion | Feb 1, 2009 |
| First posted | Feb 10, 2006 |
| Last update posted | Nov 20, 2015 |
| Countries | Canada, Czechia, Egypt, France, Greece, Jordan, Portugal, Russia, Spain, Switzerland, Turkey (Türkiye), United Kingdom |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: